US biotech firm ImmunoGen (Nasdaq: IMGN) says that SAR3419 has started Phase II testing, which triggers a $3 million milestone payment from French drug major Sanofi (Euronext: SAN) as part of a broader collaboration between the companies.
SAR3419 is a potential new treatment for CD19+ non-Hodgkin’s lymphoma (NHL) and other B-cell malignancies. In Phase I testing, this TAP compound demonstrated activity across an array of NHL histological subtypes in patients with recurrent disease. It also demonstrated activity in patients with both rituximab (Rituximab-refractory and responsive disease. SAR3419 was found to be generally well tolerated with a notable lack of significant myelosuppression.
Sanofi’s Phase II testing will focus on evaluating SAR3419 as a treatment for diffuse large B-cell lymphoma (DLBCL) and for B-cell acute lymphoblastic lymphoma (B-ALL). Currently, there are limited treatment options for B-ALL and also for DLBCL that has failed to respond to front-line therapy or recurred after treatment. DLBCL is the most common type of NHL, accounting for approximately one-third of all cases, while B-ALL accounts for a similar percentage of acute leukemia cases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze